We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Fecal Hemoglobin Stability Evaluated for FITs

By LabMedica International staff writers
Posted on 31 Oct 2017
Screening with guaiac-based fecal occult blood tests (gFOBT), followed by colonoscopy for patients who test positive, has been associated with a reduction of 15% to 33% in colorectal cancer (CRC)–related mortality.

Fecal immunochemical test (FIT) methods have been developed. More...
These immunoassays form an antibody antigen complex with the globin moiety of human hemoglobin (Hb) to generate either an immunoturbidimetric signal, which can be measured quantitatively or by lateral-flow immunochromatographic analysis, a qualitative band that can be detected visually.

A large team of scientists collaborating with those at Sunnybrook Research Institute (Toronto, ON, Canada) implemented a novel, standardized method to compare Hb stability across various fecal immunochemical tests. The stability of Hb was analyzed in collection devices inoculated with Hb-spiked feces and (1) stored at various temperatures (frozen, refrigerated, ambient, and elevated) for more than 60 days; (2) after undergoing three controlled, freeze-thaw cycles; and (3) after being transported by courier or postal services in uncontrolled temperature conditions from three locations in Ontario, Canada, to a central testing center. The team compared the stability of Hb across five different immunochemical kits and one guaiac kit.

The scientists found that the stability of Hb varied with time and temperature and by kit. Lower Hb recoveries occurred with increasing temperature and increasing time from sample collection to testing. Refrigeration provided the best stability, although results varied across kits, from 4.2 days to more than 60 days before a pre-specified threshold with less than 70% probability of the test results remaining positive was reached.

Freeze-thaw stability varied across kits and cycles. Hb recoveries from Hemoglobin NS-Plus, was 91.7% to 95.4%; while for OC-Sensor Diana, the Hb recovery was 57.6% to 74.9%. Agreement regarding Hb levels before and after transportation varied across kits, from 57% to 100%. The scientists found that the Hema-Screen SPECIFIC, was the best performer among the qualitative kits.

The authors concluded that important differences in Hb stability were found across the included fecal immunochemical tests and these findings should inform practice-based and population-based colorectal cancer screening. The study was published on October 2, 2017, in the journal Archives Of Pathology & Laboratory Medicine.

Related Links:
Sunnybrook Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.